@BenjaminBesseMD profile picture
Benjamin Besse @BenjaminBesseMD

Medical Oncologist- Lung cancer, thymic & NUT carcinomas. Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC. Tweets are my own.

Joined January 2015
  • Tweets 357
  • Following 90
  • Followers 8,135
185 Photos and videos
KRAS inhibitors in NSCLC: -G12Di: coming soon to meet a major unmet need — same activity in smokers vs never-smokers? -G12Ci: expanding field, active in both naïve and post-sotorasib/adagrasib pts. Excellent summary @GarridoLagunaMD #ESMO25
4
16
65
4,571
ALEX final OS: - crizo arm dragged down by <50% getting next-gen ALK. Lack of crossover really hurts. - 5-yr OS with alectinib ≈ 5-yr PFS with lorlatinib (CROWN), but only 18% got lorla post alect — we still don’t know the optimal sequence. #ESMO25
2
22
62
4,997
Is MET IHC predictive of amivantamab efficacy? Chrysalis-2 in EGFRmut NSCLC post-osimertinib (biopsy at resistance). Cohorts D&E: ami lazertinib | Cohort F: ami monotherapy. ORR higher with MET , but also seen in MET–. #WCLC25
4
20
85
8,772
Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver. @mihaela_aldea shows incidence, highest in ALK/RET/EGFR/ROS1. AMG193 paved the way at #ESMO24. BMS-986504 confirms druggability: 29% ORR many durable SD (slide @CharuAggarwalMD). #WCLC25
5
39
119
9,668
EGFR update 7 potential options: •3rd gen TKI: osimertinib, lazertinib, aumolertinib •Amivantamab •Pemetrexed •Carboplatin •Ivonescimab •Dato-DXd OS data favor combos upfront—but real-world ≠ trial. In RWD, ~40% of newly diagnosed pts wouldn’t qualify for FLAURA2 #WCLC25
5
63
183
16,047
Up to 50% of patients with metastatic cancer develop lung metastases, linked to poor prognosis and impaired quality of life. Our Nature Reviews Disease Primers article unpacks biology, diagnosis & treatment strategies. @LodovicaZullo @GustaveRoussy nature.com/articles/s41572-0…

Lung metastases

Nature Reviews Disease Primers - The lungs are a common metastatic site for several cancers, including colorectal cancer, primary lung cancer, breast cancer and prostate cancer. This Primer...

nature.com
6
24
76
4,206
Morning > Afternoon for IO? Evidence is mounting—retrospective and now prospective (210 pts, randomized, PFS HR 0.42 but no PD-L1 strat). Given IO’s long half-life, maybe only the timing of the first dose matters. #ASCO2025
9
40
128
22,792
Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront? Lazertinib amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami. Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
2
43
163
10,156
ICB or chemo-ICB in PD-L1≥50% advanced NSCLC? Metabolic tumor volume (tMTV) assessed by 18F FDG petscan can guide you. High tMTV lesions might have a different biology and be better candidate to chemo-ICB. @FilippoDallOlio aacrjournals.org/clincancerr…

2
19
81
6,342
NUT Carcinoma is an ultra-rare entity with a NUTM1 fusion, diagnosed by a simple IHC NUT (can look like a squamous lung cancer in a never smoker pt). Previously known as midline carcinoma, its prognosis is extremely poor. Lurbinectedin appears promising! annalsofoncology.org/article…

1
33
133
9,014
YES! De-escalation trials matter and should be much more supported by payers! Very preliminary results from the Dutch non inferiority trial DEDICATION-1 are reassuring. In France, the PULSE trial has the same hypothesis, opens soon in Belgium, Spain, Estonia and Greece! #ESMO24
7
54
169
13,949
Impressive benefit for Lenvatinib-Pembrolizumab in pts with thymic carcinoma and B3 thymoma. ORR 23.3% and mPFS 14.9m are unexpected in 2nd line or more. Lenvatinib dose matters in a subgroup analysis. Congratulations @JordiRemon #ESMO24
2
39
130
10,778
Adjuvant Durvalumab after resection of stage IB~IIIA NSCLC does not improve DFS. No predictive effect of PD-L1 expression as in KN-091/PEARLS (adj pembro): Biology of micrometastatic disease differs from matched primary tumor? Confirms that neoadjuvant is the way to go. #ESMO24
2
33
122
8,786
1st phase III trial of an ADC vs docetaxel in a biomarker selected population Tusamitamab Ravtansine targets CEACAM5, overexpressed in 25% of non sq NSCLC CARMEN LC03 did not meet the primary endpoints PFS and OS. #WCLC24
3
30
106
10,080
Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. @arousseaumd sciencedirect.com/science/ar…

8
87
240
17,675
Benjamin Besse retweeted
Fabrice Barlesi@barlesi
1 Jun 2024
Replying to @GustaveRoussy
@GustaveRoussy @ASCO #ASCO24 140 accepted abstracts, #30 oral presentations w #10 done by our experts. We’re here to exchange, collaborate and drive the next steps on the road to cure cancer. @AlbigesL
3
11
1,803
Benjamin Besse retweeted
Jordi Remon@JordiRemon
3 Jun 2024
In resected EGFR mut NSCLC after chemo 6 mo vs 12 mo icotinib (1st G EGFR TKI) similar DFS and OS despite only 70% completed txt. Adj OSI x 3y: 4y DFS 73% 5yOS 88%. Data in line with shorter treatment and with 1st G TKI ➡️We should explore descalating txt in this setting #ASCO24
1
12
41
4,087
Another promising B7H3 ADC in pts with Small Cell Lung Cancer. « SuperTopoi » payload. DAR=4. Very early data. No ILD. Unconfirmed ORR 61.3%. #ASCO24
1
23
58
8,910
LIFETIME osimertinib after a treatment with curative intent? In pts with EGFRmut stage III NSCLC, chemo-radiotherapy can CURE pts. Were pts in LAURA properly staged by petscan/brain RMI? Why not using MRD to select patient? Strong concerns when OS is not positive. #ASCO24
8
72
201
27,922
1st generation KRAS inhibitors: a piece of the puzzle is still missing. #ASCO24 Hope it will be enough to convince refractory HTAs to refund the drug! @KRASKickers
1
10
50
4,703
Load more